Sol Gel Technologies Ltd - Asset Resilience Ratio
Sol Gel Technologies Ltd (SLGL) has an Asset Resilience Ratio of 43.34% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read SLGL total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Sol Gel Technologies Ltd's Asset Resilience Ratio has changed over time. See Sol Gel Technologies Ltd book value and equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Sol Gel Technologies Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Sol Gel Technologies Ltd market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $12.97 Million | 43.34% |
| Total Liquid Assets | $12.97 Million | 43.34% |
Asset Resilience Insights
- Very High Liquidity: Sol Gel Technologies Ltd maintains exceptional liquid asset reserves at 43.34% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Sol Gel Technologies Ltd Industry Peers by Asset Resilience Ratio
Compare Sol Gel Technologies Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Sol Gel Technologies Ltd (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Sol Gel Technologies Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 43.34% | $12.97 Million | $29.92 Million | +30.96pp |
| 2024-12-31 | 12.38% | $4.44 Million | $35.85 Million | -54.93pp |
| 2023-12-31 | 67.31% | $30.48 Million | $45.29 Million | +21.89pp |
| 2022-12-31 | 45.42% | $21.18 Million | $46.63 Million | +11.95pp |
| 2021-12-31 | 33.47% | $23.16 Million | $69.19 Million | -39.30pp |
| 2020-12-31 | 72.77% | $43.05 Million | $59.16 Million | +5.94pp |
| 2019-12-31 | 66.83% | $40.97 Million | $61.30 Million | -15.92pp |
| 2018-12-31 | 82.75% | $57.66 Million | $69.68 Million | +56.63pp |
| 2017-12-31 | 26.12% | $4.00 Million | $15.31 Million | -- |
About Sol Gel Technologies Ltd
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treat… Read more